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REVIEW
Lithium’s antiviral effects: a potential drug 
for CoViD-19 disease?
Andrea Murru1†, Mirko Manchia2,3,4†, Tomas Hajek5, René E. Nielsen6,7, Janusz K. Rybakowski8,9, 
Gabriele Sani10,11, Thomas G. Schulze12,13,14,15,16, Leonardo Tondo17,18,19, Michael Bauer20*  and for the 
International Group for The Study of Lithium Treated Patients (IGSLi)
Abstract 
Background: Since its introduction in modern medicine, naturalistic observations emerged about possible uses of 
lithium treatment for conditions different from recurring affective disorders, for which it is still a first-line treatment 
option. Some evidence about the antiviral properties of lithium began in the early 1970s, when some reports found 
a reduction of labial-herpetic recurrences. The present review aims to present most of the pre-clinical and clinical evi-
dence about lithium’s ability to inhibit DNA and RNA viruses, including Coronaviridae, as well as the possible pathways 
and mechanisms involved in such antiviral activity.
Main body: Despite a broad number of in vitro studies, the rationale for the antiviral activity of lithium failed to 
translate into methodologically sound clinical studies demonstrating its antiviral efficacy. In addition, the tolerability 
of lithium as an antiviral agent should be addressed. In fact, treatment with lithium requires continuous monitoring 
of its serum levels in order to prevent acute toxicity and long-term side effects, most notably affecting the kidney and 
thyroid. Yet lithium reaches heterogeneous but bioequivalent concentrations in different tissues, and the anatomical 
compartment of the viral infection might underpin a different, lower need for tolerability concerns which need to be 
addressed.
Conclusions: Lithium presents a clear antiviral activity demonstrated at preclinical level, but that remains to be con-
firmed in clinical settings. In addition, the pleiotropic mechanisms of action of lithium may provide an insight for its 
possible use as antiviral agent targeting specific pathways.
Keywords: Bipolar disorder, GSK-3β, Inositol, Virus, Coronavirus
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Background
More than 70  years since introduction to routine clini-
cal practice, lithium remains the first-line option for the 
treatment of bipolar disorder (BD), having the strongest 
evidence supporting both its acute and long-term effi-
cacy in patients with BD (Yatham et al. 2018). Indications 
for use of lithium in BD span across different age groups, 
from children/adolescents (Duffy et  al. 2018; Duffy and 
Grof 2018) to elder populations (Young et  al. 2017). In 
addition to its established clinical efficacy, lithium is 
associated with a reduction of suicide risk (Tondo and 
Baldessarini 2018), which is exerted irrespective of its 
mood-stabilizing properties (Manchia et  al. 2013; Sarai 
and Mekala 2018) and possibly at concentrations as low 
as those found in drinking water (Barjasteh-Askari et al. 
2020). Importantly, lithium contributes to reduction of 
depressive morbidity, which is predominant in the clini-
cal course of BD (Murru et al. 2017a; Samalin et al. 2016), 
and is associated with an excess of mortality (Baldessarini 
et al. 2020).
Despite the well-established efficacy of lithium, its 
use has declined in the last decades in some parts of the 
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world, partly due to the safety concerns, which require 
proper therapeutic monitoring, and to strong market-
ing strategies supporting the use of anticonvulsants and 
antipsychotics, which however may be less effective 
(Tondo et al. 2019). Recent evidence shows that the renal 
toxicity and teratogenic effects of lithium are much less 
pronounced than initially thought (Fornaro et  al. 2020; 
Nielsen et al. 2018).
Lithium molecular effects
Lithium has a pleiotropic mechanism of action modulat-
ing first, second and third messengers (and their down-
stream molecular cascades),higher order biological 
systems (Alda 2015; Quiroz et  al. 2004), including the 
circadian clock rhythm (McCarthy 2019) and the neu-
ral plasticity (Alda 2015). Although a detailed review of 
lithium molecular effects lies outside the scope of this 
review, some mechanisms might be relevant with regard 
to its antiviral effects: [a] the inhibition of the phosphati-
dylinositol signalling pathway via suppression of the ino-
sitol-polyphosphate 1-phosphatase (IPPase) and inositol 
monophosphate phosphatase (IMPase) (Yu and Green-
berg 2016), [b] the regulation of autophagy (Motoi et al. 
2014), and [c] the inhibition of the glycogen synthase 
kinase-3, isoform β (GSK-3β) (Quiroz et al. 2004).
Experimental evidence shows that both IMPase and 
IPPase, which are members of a group of at least four 
magnesium-dependent phosphomonoesterases, are 
significantly inhibited at therapeutic serum concentra-
tions of lithium (0.6–1.2  mM/l) (Quiroz et  al. 2004). 
Inositol is the essential substrate for the synthesis of 
phosphatidylinositol (PI), from which PI(4,5) biphos-
phate (P2) is produced (Yu and Greenberg 2016). With 
the receptor-mediated activation of the phospholipase 
C (PLC), PI(4,5)P2 is cleaved to form inositol-1,4,5-
triphosphates (IP3) and 1,2-diacylglycerol (DAG) (Streb 
et  al. 1983). The IP3 can be either recycled to myo-
inositol by a series of dephosphorylations catalysed by 
IPPase and IMPase or, alternatively, can be phosphoryl-
ated sequentially to form IP4, IP5, IP6, IP7 and IP8 by a 
series of kinases, including the inositol polyphosphate 
multikinase (IPMK) and inositol pentakisphosphate 
2-kinase (IPPK) (Balla 2013; Wei et  al. 2018; Yu and 
Greenberg 2016). The depletion of myoinositol deter-
mined by the lithium-induced inhibition of IMPase 
and IPPase, could in turn provoke the dampening of 
PI signalling with decreased downstream levels of ino-
sitol phosphates. Although experimental data suggest 
that long-term, rather than short-term, lithium expo-
sure can dampen PI signalling (Wei et  al. 2018), this 
molecular effect if of great interest in terms of potential 
antiviral effects. Indeed, IP6 appears to be a key factor 
in substantially increasing the viral stability of HIV, an 
RNA virus, facilitating the accumulation of newly syn-
thesized DNA inside the capsid (Mallery et  al. 2018). 
It is conceivable that decreased levels of IP6 would 
decrease the ability of HIV of replicating effectively.
Replicated data show that lithium promotes autophagy, 
the physiological process responsible for the quality con-
trol of essential cellular components by purging the cell 
of old or damaged organelles in several neuropsychiatric 
conditions (Motoi et  al. 2014). The beneficial effect of 
lithium on autophagy has been demonstrated in several 
neurodegenerative disorders, including Huntington’s dis-
ease (Sarkar et al. 2005) and amyotrophic lateral sclerosis 
(Fornai et al. 2008) and it appears to be mediated through 
its modulatory effects on GSK-3β and IMPase (Motoi 
et al. 2014). As several DNA and RNA viruses are able to 
inhibit the autophagy pathway to increase their survival 
(Mehrbod et  al. 2019), this molecular effect of lithium 
may decrease the chance of the viruses’ survival.
Finally, the relevant inhibitory action of lithium on 
GSK-3ß, a serine-threonine kinase that influences more 
than one hundred substrates modulating cell survival, 
gene expression and microtubule formation, appears rel-
evant (Alda 2015; Quiroz et al. 2014). In fact, the inhibi-
tion of GSK-3ß during the later stages of infection with 
Dengue virus-2 (DENV-2), an RNA virus, resulted in a 
reduction of viral titres in hepatocarcinoma cell (Huh-7) 
and Vero cell lines (Cuartas-López and Gallego-Gómez 
2020). In addition, lithium-induced inhibition of GSK-
3ß led to a significantly more decreased production of 
chronic hepatitis C virus (HCV) viral particles in treated 
vs. untreated human hepatoma cell lines (Sarhan et  al. 
2017).
Lithium and immune system
Immune dysfunction seems to plays a key role in the 
onset and progression of BD in a substantial propor-
tion of individuals (Rosenblat 2019). Lithium has long 
been recognized as an immune modulating drug (Ryba-
kowski 1999), with both anti-inflammatory (e.g., sup-
pression of cyclooxygenase-2 expression, inhibition of 
interleukin (IL)-1β and tumour necrosis factor-α pro-
duction, and enhancement of IL-2 and IL-10 synthesis) 
and pro-inflammatory (e.g., induction of IL-4, IL-6 and 
other pro-inflammatory cytokines synthesis) action (Nas-
sar and Azab 2014). In the long term, however, the use 
of lithium has been significantly associated with a nor-
malization of cytokine levels, balancing the disruptions 
observed in BD patients (Van Den Ameele et  al. 2016). 
Therefore, lithium exerts a combined action that involves 
multiple pathways. This discloses different potential 
applications of lithium which remain largely unexplored 
(Chiu et al. 2013).
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Aim of the review
The recent pandemic of the 2019 novel coronavirus 
(SARS-CoV-2) causing the coronavirus disease (CoViD-
19) has emphasized the need for any effective treatment, 
given the few therapeutic options available (Guan et  al. 
2020). The only therapeutic strategies currently available 
are those applied in intensive care units, i.e. using anti-
inflammatory agents and anticoagulants to prevent the 
respiratory insufficiency and the vasculitis. Some anti-
viral agents, namely the recently FDA-approved rem-
desivir, help the viral elimination although conclusive 
evidence on its efficacy is still lacking (Grein et al. 2020; 
Ledford 2020). In addition, almost all countries have sug-
gested or disposed lockdown measures able to tackle 
down the spread of the infection such as social distanc-
ing, quarantine, and isolation (Baden and Rubin 2020), 
all presenting major challenges and limitations (Niud and 
Xu 2020). The development of a vaccine represents the 
ideal therapeutic approach to the CoViD-19 pandemic, 
but despite some progress it can be still lengthy. At the 
moment, symptomatic approaches to the infection and 
its complications, combined with re-purposing of thera-
peutic options already available for other conditions, are 
two main areas of action against this viral pandemic (Lu 
2020).
In this context, we aim to review the preclinical and 
clinical evidence on the antiviral effects of lithium, offer-
ing a perspective for its potential use in clinical settings. 
For the sake of clarity, in each section we will present first 
the effect of lithium on DNA viruses and then on RNA 
viruses, including the family of Coronaviridae.
We performed a broad literature search including the 
keywords “lithium” and “antiviral”, “viral”, alone and with 
“*” wildcard, in order to screen for the widest result out-
put. We cross-checked references for articles of interest. 
We excluded from our results opinion articles, editorials 
or reviews, and articles which were not written in English 
language.
Main text
Preclinical evidence
DNA viruses
The first report on lithium antiviral effects dates back to 
1970, when Neurath et  al. (1970) showed that lithium 
iodide disrupted the viral capsid of adenovirus type 7 
(Neurath et  al. 1970). Subsequently, lithium iodide’s 
ability to degrade the nucleocapsid was observed also 
in the Herpes simplex virus (HSV) (McCombs and Wil-
liams 1973). In addition, lithium was first shown to 
inhibit the replication of type 1 and type 2 HSV at con-
centrations of 5 mM/l and of the pseudorabies and vac-
cinia viruses (Skinner et al. 1980). This effect extended 
also to pseudorabies and vaccinia virus (Skinner et  al. 
1980). Further support was provided for the in  vitro 
antiviral activity of lithium on HSV in Vero cells and 
rabbit (Trousdale et  al. 1984). However, the same 
authors were unable to detect a reduction in the reac-
tivation of latent infection in rabbits (Trousdale et  al. 
1984).
Cernescu et  al. (1988) observed a reduction in virus 
replication in human embryo fibroblasts cultures 
infected with measles or HSV when pre-treated with lith-
ium chloride at concentrations of 1–10 mM/l (Cernescu 
et al. 1988). The maximum effect was obtained by a 1-h 
treatment with 10 mM/l lithium chloride, preceding viral 
infection by 19–24 h (Cernescu et al. 1988). Further, they 
showed that intermittent treatment with 10 mM lithium 
chloride of cultures persistently infected with measles 
or HSV obtained from human myeloid K-562 cell line 
showed a reduction in the extracellular virus yield (Cer-
nescu et al. 1988). Of interest, lithium not only reduced 
vital replication, but also restored the synthesis of almost 
all host-cell proteins, including fibronectin, type IV colla-
gen, thrombospondin (TSP) and proteoglycans, which is 
typically suppressed by HSV (Ziaie and Kefalides 1989). 
Again, lithium was more effective at the higher concen-
tration (30  mM/l) and when the compound was added 
to the culture at the time of infection rather than after 
adsorption of HSV (Ziaie and Kefalides 1989).
One proposed possible mechanism of lithium inhibit-
ing effect on HSV DNA synthesis is the displacement 
of potassium from a potassium-dependent biochemi-
cal event or through other physiological change follow-
ing the loss of cellular potassium (Hartley et al. 1993). In 
addition, it is plausible that lithium also directly inhibits 
viral replication. Indeed, lithium chloride at 30 mM sup-
pressed the synthesis of viral polypeptides, whereas the 
synthesis of host proteins was maintained. In particu-
lar, the mRNAs for viral proteins, including the DNA 
polymerase, were nearly undetectable when lithium 
was added with the virus to the endothelial cell cultures 
infected with HSV-1 (Ziaie et al. 1994).
Some studies focused on the effects of lithium on virus 
of the Parvoviridae family. Chen et  al. (2015) reported 
on the inhibition of porcine parvovirus (PPV) replica-
tion in swine testis (ST) cells by lithium chloride in a 
dose-dependent fashion, with statistically significant 
effects observable already at 5 mM/l (Chen et al. 2015). 
As for other viruses, the antiviral effect of lithium chlo-
ride occurred in the early phase of PPV replication (Chen 
et al. 2015). In addition, Zhout et al. (2015) showed that 
lithium not only suppressed the synthesis of viral DNA 
and proteins of canine parvovirus in a dose-dependent 
manner, but also inhibited viral entry into feline kidney 
cells cultures (Zhou et al. 2015).
Page 4 of 9Murru et al. Int J Bipolar Disord            (2020) 8:21 
RNA viruses
A series of studies have explored the effects of lithium 
antiviral activity on RNA viruses both in cellular and ani-
mal models. Gallicchio et al. (1993) explored the hypoth-
esis that lithium treatment might decrease the severity of 
murine acquired immune deficiency syndrome (MAIDS) 
induced by the murine leukaemia retrovirus (Gallicchio 
et  al. 1993). Lithium-treated animals (1  mM/l) demon-
strated a marked reduction in the development of lym-
phadenopathy and splenomegaly suggesting a potential 
role of lithium in the pathophysiological processes asso-
ciated with retroviral infections (Gallicchio et al. 1993).
These antiviral effects appear to extend to other RNA 
viruses such as those pertaining to the family of Corona-
viridae. Harrison et al. (2007) tested the effect of lithium 
chloride on the replication of avian coronavirus infec-
tious bronchitis virus (IBV) in cell culture using two 
model cell types: Vero cells, an African Green monkey 
kidney-derived epithelial cell line, and DF-1 cells, an 
immortalized chicken embryo fibroblast cell line (Har-
rison et al. 2007). When treated with a range of lithium 
chloride concentrations (0, 5, 10, 25 or 50  mM/l), IBV 
RNA and protein levels, as well as viral progeny produc-
tion were reduced in a dose-dependent manner in both 
cell types, with data indicating that the inhibition was 
determined by a cellular, by inhibiting RNA synthesis, 
rather than a virucidal effect (Harrison et  al. 2007), an 
effect also confirmed in a subsequent study by Li et  al. 
(2009) (Li et al. 2009). Furthermore, in Vero cells, lithium 
chloride showed effectiveness in suppressing infection of 
the porcine epidemic diarrhoea virus by inhibiting of the 
virus entry, replication and apoptosis (Li et al. 2018). In 
type II porcine reproductive and respiratory syndrome 
virus lithium chloride reduced RNA production and pro-
tein transduction (Cui et al. 2015). Furthermore, lithium 
chloride at concentrations of 10–60  mM significantly 
inhibited viral replication of porcine deltacoronavirus 
(PDCoV) in porcine kidney cells (LLC-PK1) compared to 
mock-treated cells (Zhai et al. 2019). The antiviral effects 
of lithium chloride occurred at the early stage of PDCoV 
replication, and was associated to the inhibition of the 
PDCoV-induced apoptosis in LLC-PK1 cells (Zhai et  al. 
2019). Finally, lithium chloride showed in vitro ability to 
limit both early and late stages of infection and to inhibit 
apoptosis in another porcine coronavirus causing trans-
missible gastroenteritis (Ren et al. 2011).
In another study, lithium chloride inhibited the replica-
tion of the foot-and-mouth disease virus (FMDV) (Zhao 
et al. 2017). The viral titres of FMDV decreased in a dose-
dependent manner in cells cultures, although it did not 
affect FMDV attachment stage and entry stage in the 
course of its life cycle (Zhao et al. 2017). Finally, two stud-
ies confirmed the inhibitory effects of lithium on viral 
replication in other RNA viruses such a feline calicivirus 
(FCV) (Wu et al. 2015), and mammalian orthoreoviruses 
(Chen et al. 2016). Wu et al. (2015) showed that lithium 
chloride effectively suppressed the replication of FCV 
strain F9 in Crandell-Reese feline kidney (CRFK) cells 
in a dose-dependent manner and inhibited the virus-
induced cytopathic effect (Wu et  al. 2015). The dose-
dependent inhibition of viral replication was observed 
also in reovirus infected Vero cells (Chen et al. 2016).
Clinical evidence
DNA viruses
Early observations reported that depressed and bipolar 
depressed patients presented increased antibodies titres 
to HSV (Lycke et al. 1974). Few years later, between 1979 
and 1983, some cases were published reporting on the 
possible antiviral effect of lithium in humans, with the 
observed remission of labial (HSV1) herpes in 3 lithium 
carbonate-treated affective patients (Gillis 1983; Lieb 
1979). In these cases, lithium was initiated for a chronic 
recurring affective disorder in patients with personal 
history for frequent labial herpes manifestations, and it 
reduced or interrupted herpetic recurrences. Further-
more, at lithium discontinuation, labial herpes recurred 
with previous frequency.
These serendipitous findings awoke interest on the 
possible immune-modulatory and/or antiviral action 
of lithium. A retrospective study followed (Amsterdam 
et  al. 1990), including a total of 263 patients. Of them, 
177 subjects received  lithium  carbonate prophylaxis, 
while a comparison group of 59 subjects received anti-
depressant monotherapy for a major affective disorder. 
Overall, 90 out of 236 subjects reported the presence of 
recurrent labial herpes infections, 63/177 (36%) on lith-
ium and 27/59 (46%) on antidepressants with not statis-
tically significant difference in the rates. However, the 
mean pre-treatment recurrence rate for labial herpes 
infections (1.6 ± 2.6/year) significantly decreased dur-
ing treatment (0.8 + 1.8/year, p < 0.001). In contrast, the 
same recurrence rates showed no significant changes in 
antidepressant-treated patients (Amsterdam et al. 1990). 
Of note, the reduction of HSV recurrences was higher in 
patients with lithium concentrations ≥ 0.65 mmol/l than 
in those with lower concentration (respectively, 70% vs. 
54%) and with erythrocyte lithium levels ≥ 0.35  mmol/l 
than patients with lower concentrations (respectively, 
81% vs. 49%) (Rybakowski and Amsterdam 1991). After-
wards, the Polish arm (28 patients) of the previous study 
was followed-up in an uncontrolled prospective report to 
further study the prophylactic effect of lithium carbonate 
against HSV recurrences (Rybakowski et  al. 1996). The 
observed reduction of HSV recurrences did not correlate 
with lithium concentrations in serum or erythrocytes.
Page 5 of 9Murru et al. Int J Bipolar Disord            (2020) 8:21  
Importantly, lithium concentration in plasma is 
considerably lower than the concentrations show-
ing anti-viral properties in in  vitro trials, but lithium 
concentration in saliva is considerably higher than in 
plasma, and both concentrations show bioequivalence 
(Murru et  al. 2017b), so that a direct and topic effect 
on labial mucosae is hypothesized. The observation that 
lithium may heterogeneously accumulate in different 
tissues prompted a randomized double blind, placebo-
controlled trial on the use of topic 8% lithium succinate 
ointment in 73 patients with recurring genital (HSV2) 
herpes (Skinner 1983). The ointment was applied 4 
times a day for 7  days, swabs from lesions obtained 
at day 4 or 5 after onset of lesions, and a quantitative 
measure of HSV2 was performed. The median dura-
tion of pain/discomfort was reduced in lithium-treated 
patients from 7 to 4  days (p < 0.05), while time to full 
healing was decreased from 8 days in the placebo arm 
to 7  days in the active drug arm. HSV2 excretion at 
day 4 or 5 was present in 11/20 (55%) placebo-treated 
compared with 5/37 (14%) lithium-treated patients, 
and virus concentration in lithium group was reduced 
by a 30-fold as compared to the concentration in the 
placebo arm (p < 0.05). Lithium succinate ointment 
showed good active tolerability, with no side effects 
reported (Skinner 1983).
Positive results were also obtained in an uncontrolled 
study conducted on a sample of 42 Polish patients (38% 
female) with recurrent labial (HSV1) herpes with ill-
ness duration of 1–25  years and frequency of recur-
rences varying from very frequent (1/month) to rare (1 
recurrence every 7  months or more) (Rybakowski et  al. 
1991). Lithium succinate 8% ointment was the tested 
drug, applied topically within 1–4  days of lesion onset, 
2–7 times days the first 3  days and 1–2 times per day 
thereafter. All patients achieved full recovery in 2–7 days 
(mean 4 days), with subjective complaints alleviated after 
the first 1–3 applications. During the follow-up (ranging 
4–12 months), when relapse was observed (6/42), lesions 
never occurred in the same location of the lesion at study 
entry (Rybakowski et al. 1991).
Oral lithium carbonate treatment was tested as a pro-
phylactic recurrence treatment of HSV-2 in two ran-
domized, placebo-controlled trials. In the first one 
(Amsterdam et al. 1991), 10 women with recurrent geni-
tal HSV infection entered oral lithium for 12  months, 
and were followed for a total duration of 18  months. 
During the active treatment phase, average daily lith-
ium doses were 587 + 49  mg and average plasma levels 
were 0.51 mmol/l. Patients in the active arm of the study 
showed a trend towards average monthly reduction in 
number and duration of herpetic lesions, maximum 
symptom severity and clinical severity.
In the second randomized controlled trial (Amsterdam 
et  al. 1996), 11 patients (9 women), aged 38 ± 11  years 
(range 28–65) and with a personal history of HSV-2 
infection with four or more recurrences were randomly 
assigned to lithium (n = 6) or placebo (n = 5) for at least 
five months. The mean number of manifestations in the 
year before study entry was 12 ± 8 (range 4–30), each 
episode lasting 12 ± 8  days. Mean lithium daily dosage 
was 437 ± 185  mg (range 150–900  mg/day), with serum 
concentration of 0.56 ± 0.20 mmol/l. Differences between 
study arms were statistically nonsignificant and point-
ing to an overall attenuation of HSV-2 in lithium-treated 
patients, while placebo-treated patients showed a wors-
ening in 3 of 4 infection clinical outcomes. Last, a case 
reports an adolescent female BD patient, with a history of 
chronic active Epstein Barr virus infection and recurrent 
acute pancreatitis, who achieved apparent control of the 
viral infection with lithium monotherapy (Pavuluri and 
Smith 1996).
RNA viruses
Early reports on lithium antiviral properties reported 
minimal or no effect on RNA viruses, apart from an 
anecdotic observation of reduced symptoms of common 
cold and influenza in a retrospective study focused on 
anti-herpetic action of lithium (Rybakowski and Amster-
dam 1991).
A proof-of-concept study (Puertas et  al. 2014), was 
conducted on 9 patients affected by human immuno-
deficiency virus-1 (HIV) previously recruited in a trial 
investigating the possible neurocognitive protecting 
effect of rivastigmine, compared with lithium carbon-
ate (Muñoz-Moreno et  al. 2017). The aim of the proof-
of-concept study was to study the effect of lithium on 
HIV-1 expression and reservoir size in the CD4þ T cells 
of virologically suppressed patients. Mean time from 
HIV-1 diagnosis was 10.7 ± 6.5 years, and the mean time 
of sustained virological suppression was 5.3 ± 3.4  years. 
Patients started with an initial lithium carbonate dose of 
400 mg/day and lithium blood levels of 0.4–0.8 mmol/l. 
At week 2, cell-associated HIV-1 RNA transcripts 
decreased in 5 of 6 patients. At week 4, the reduction in 
viral transcription levels was of 40%. Of note, viral tran-
scription later increased so that at week 12 of treatment 
all patients recovered their initial transcription pattern. 
Viremia decreased from 67% at baseline to 44% immedi-
ately after beginning lithium, possibly by activation of the 
ß-catenin signalling, but rose to 87% at week 12. These 
data reflected the patterns of expression of HIV-1 in cir-
culating CD4þ T cells. The proportion of circulating CD4þ 
T cells harbouring proviral DNA was also measured. At 
baseline, HIV-1 copies were 1173 per million CD4þ T 
cells (interquartile range: 388–2343) and at week 4, they 
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dropped to 582 copies (373–1606), a significant reduc-
tion in the size of the proviral reservoir in CD4þ T cells 
(19% median decrease, p = 0.03), later lost at week 12 
(Puertas et al. 2014).
A retrospective study conducted on a sample of 236 
affective disorder patients 177 taking lithium carbon-
ate and 59 taking antidepressants (tricyclics, monoam-
ine oxidase inhibitors or fluoxetine) on a chronic basis, 
investigated the possible effect of psychotropic drugs in 
reducing the reported yearly recurrence rate of flu-like 
infections (Amsterdam et al. 1998). Results of this prelim-
inary report showed a statistically significant reduction in 
mean yearly rates of flu-like infections in lithium- (pre-
treatment 1.48 ± 1.13 vs. post-treatment 1.14 ± 1.20, 
p < 0.001), but not antidepressant-treated patients.
Discussion
In this narrative review we have summarized the studies 
on preclinical and clinical efficacy of lithium as antiviral 
agent. A series of considerations should be made with 
regard to each set of findings. In general, early pre-clin-
ical studies converge on the ability of lithium to inhibit 
viral replication. This effect has been extensively found 
on a wide group of DNA viruses, mostly of the Herpes-
viridae family, including the HSV-1, HSV-2, Epstein-Barr 
virus, Cytomegalovirus, and adenovirus, and it extends to 
other RNA viruses, among which are the reovirus, HVC, 
avian leucosis virus, and different viruses of the Corona-
viridae family (Nowak and Walkowiak 2020).
However, in most cases findings from in  vitro studies 
lack supportive clinical evidence. Indeed, the available 
clinical evidence appears scant and generally of low qual-
ity, as it is limited to case series and retrospective stud-
ies. In fact, only two randomized controlled studies have 
been published, whose results weakened by small sample 
sizes and consequent inadequate statistical power. It is 
possible that the insufficient proper clinical evidence of 
the antiviral effects of lithium is a reflection of its status 
as a drug without strong marketing support. Indeed, after 
two seminal randomized clinical trials (Amsterdam et al. 
1991, 1996), there have been no further investigation of 
this important property of lithium, although supported 
by some preclinical evidence summarized in this review. 
The gap in the knowledge of lithium clinical spectrum 
of efficacy beyond the well-known effects in the preven-
tion of mood-disorders recurrence has substantial impli-
cations in the context of the current pandemic of the 
CoViD-19.
The pandemic has first expanded from the Wuhan 
region in China, and has quickly spread to Europe and to 
the rest of the world, that, if not still struggling for an ade-
quate control of the pandemic (Guan et al. 2020), remains 
in alert for future, possibly seasonal manifestation of the 
outbreak (Kissler et  al. 2020). Whilst the development 
of a CoViD-19 vaccine is the desired advancement for 
the control of the pandemic, the growing prevalence of 
symptomatic CoViD-19 patients calls for a broadening of 
possible therapeutic options.  The development of treat-
ments for CoViD-19 is feasible either by testing known or 
unknown existing broad-spectrum antiviral treatments 
(Baden and Rubin 2020), like the recently FDA-approved 
remdesivir (Grein et  al. 2020). Although, the most rea-
sonable step hast to be the development of new, specific 
compounds, would require a considerable amount of 
time for the entire drug-development pipeline. Alterna-
tively, repurposing of some drugs marketed with other 
clinical indications than antiviral, but showing efficacy 
against the SARS-CoV-2 could be a viable option. Lith-
ium may have a relevant role in this scenario.
As summarized by our group and by others (Nowak 
and Walkowiak 2020) the antiviral effects of lithium 
extend to several components of the Coronaviridae fam-
ily. In addition, further support, although indirect, for the 
role of lithium appears to come from advanced analysis 
combining structure-assisted drug design, virtual drug 
screening and high-throughput screening to repurpose 
existing drugs to target SARS-CoV-2, and particularly 
its main protease  Mpro, which is an essential component 
for viral replication (Jin et  al. 2020). Indeed, this study 
showed that ebselen, a lithium mimetic agent (Singh 
et  al. 2013), determined an enzymatic inhibition of the 
protease  Mpro activity, a finding further substantiated the 
in vitro observation of a strong antiviral effect at a con-
centration of 10 μM in CoViD-19 virus infected Vero cells 
(Jin et  al. 2020). This appears relevant given that ebse-
len shares a distinct molecular mechanism with lithium, 
namely the inhibition of IMPase (with consequent damp-
ening of PI signalling) which induces lithium-like effects 
on mouse behaviour, reversed by inositol (Pisanu et  al. 
2016; Singh et al. 2013).
However, the repurposing of lithium may pose spe-
cific problems. Among them, regulatory requirements 
which underwent an attempt to harmonize between 
national and federal medication agencies dating as 
back as 2007 (Mariz et al. 2016). Furthermore, the need 
for medical plausibility as well as for a solid scientific 
rationale, both at pre-clinical and clinical level, needs 
to combine with complex safety/surveillance moni-
toring, which may benefit from large, structured and 
integrated nationwide data sources (Crisafulli et  al. 
2019). Lithium’s safety and tolerability profile is a major 
concern in clinical practice, and its narrow therapeu-
tic window needs accurate monitoring to optimize its 
effectiveness as well as increase treatment adherence 
(Nolen et  al. 2019). Experimental data show that viral 
inhibition starts to occur at very high concentrations 
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of lithium, typically close to the toxicity threshold 
reported in human pharmacokinetic studies (1.0–
1.2 mM/l). However, it should be noted that, although 
the in  vitro antiviral effects are more prominent at 
higher concentrations of lithium, some level of activity 
is detectable even at lower doses. In addition, it is con-
ceivable that, as previously reported for saliva, specific 
anatomic compartment can have higher concentra-
tions of lithium than those detectable in serum. Thus, 
as demonstrated for labial HSV, the normal therapeutic 
levels could be sufficient to obtain some degree of anti-
viral efficacy. Furthermore, specific dosage regimens, 
such as that including the evening loading of lithium, 
might be more effective in this regard and should be 
considered in eventual clinical studies.
On the other hand, considering the viral direct liver 
damage CoViD-19 (Zhang et al. 2020) and the possible 
hepatotoxicity to either antiviral drugs, i.e. remdesivir, 
or the underlying disease (Grein et  al. 2020), lithium’s 
null effect on hepatic function could prove useful. In 
fact, despite lithium treatment for CoViD-19 in the 
general population seems unlikely, when tailoring a 
treatment plan for CoViD-19in patients affected by BD, 
the awareness of lithium’s antiviral effect could opti-
mize the inevitable polypharmacy. Patients affected by 
BD present increased rated of cardiovascular disease, 
metabolic syndrome, diabetes, overweight/obesity, 
hypertension and smoking status compared to the gen-
eral population (Vancampfort et al. 2015; Vancampfort 
et al. 2013). Such comorbidities associate with a worse 
CoViD-19 outcome, both directly with increased in-
hospital deaths due complications (Mehra et  al. 2020) 
and indirectly due to worst outcomes when subjected 
to mechanical ventilation (Martínez-Alés et al. 2020).
We believe that the findings summarized should 
motivate two types of investigations to build a ration-
ale for clinical investigations on its effects on Corona-
viridae. One set of evidence should come from in vitro 
studies directly testing the antiviral effect of lithium in 
cell cultures infected with the SARS-CoV-2. This type 
of tests may require also a relatively long time, whereas 
naturalistic and simple investigations could aim at iden-
tifying effects on the CoViD-19 on infected lithium-
treated and untreated subjects.
One final remark should be made concerning the 
methodology applied in this work. As described, we 
performed a narrative review that lacks the proper sys-
tematic approach needed for a qualitative (or quantita-
tive) synthesis of the literature. However, it should be 
noted that, even if we did not apply specific inclusion 
or exclusion criteria, our search was quite thorough 
and included also studies tracked via accurate reference 
checking.
Conclusions
In conclusion, lithium has clear antiviral activity that is 
demonstrated at preclinical level but remains to be estab-
lished in clinical settings. A direct inhibitory effect of 
lithium on viruses of the Coronaviridae family and on the 
SARS-CoV-2 in particular remains a key, and yet unan-
swered research question.
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